{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:16:52Z","timestamp":1775855812968,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR072007"],"award-info":[{"award-number":["RS-2022-NR072007"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR072007"],"award-info":[{"award-number":["RS-2022-NR072007"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR072007"],"award-info":[{"award-number":["RS-2022-NR072007"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR072007"],"award-info":[{"award-number":["RS-2022-NR072007"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR072007"],"award-info":[{"award-number":["RS-2022-NR072007"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR072007"],"award-info":[{"award-number":["RS-2022-NR072007"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR072007"],"award-info":[{"award-number":["RS-2022-NR072007"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00445180"],"award-info":[{"award-number":["RS-2024-00445180"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00445180"],"award-info":[{"award-number":["RS-2024-00445180"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00445180"],"award-info":[{"award-number":["RS-2024-00445180"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR072007"],"award-info":[{"award-number":["RS-2022-NR072007"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-01175-w","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:56:02Z","timestamp":1763556962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel peptide-based strategy to enhance GBA1 expression for treating Parkinson\u2019s disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Hyerynn","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyeon","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Guk","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeonwoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Younwoo","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geon-Hwi","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Hyeok","family":"Pyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihoon","family":"Nah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Min","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Ho","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Jin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangjune","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"1175_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1175_CR2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N. Engl. J. Med 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med"},{"key":"1175_CR3","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.neuro.2009.06.009","volume":"30","author":"AB Manning-Bog","year":"2009","unstructured":"Manning-Bog, A. B., Schule, B. & Langston, J. W. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 30, 1127\u20131132 (2009).","journal-title":"Neurotoxicology"},{"key":"1175_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/brain\/awt367","volume":"137","author":"KE Murphy","year":"2014","unstructured":"Murphy, K. E. et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson\u2019s disease. Brain 137, 834\u2013848 (2014).","journal-title":"Brain"},{"key":"1175_CR5","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/gcc.20709","volume":"48","author":"V Fulci","year":"2009","unstructured":"Fulci, V. et al. Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. Genes Chromosomes Cancer 48, 1069\u20131082 (2009).","journal-title":"Genes Chromosomes Cancer"},{"key":"1175_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37\u201352 (2011).","journal-title":"Cell"},{"key":"1175_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ymgme.2012.11.010","volume":"108","author":"TL Yap","year":"2013","unstructured":"Yap, T. L., Velayati, A., Sidransky, E. & Lee, J. C. Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol. Genet Metab. 108, 56\u201364 (2013).","journal-title":"Mol. Genet Metab."},{"key":"1175_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg, M. E. et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 455\u2013463 (2012).","journal-title":"Ann. Neurol."},{"key":"1175_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/acn3.177","volume":"2","author":"EM Rocha","year":"2015","unstructured":"Rocha, E. M. et al. Progressive decline of glucocerebrosidase in aging and Parkinson\u2019s disease. Ann. Clin. Transl. Neurol. 2, 433\u2013438 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1175_CR10","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/brain\/awv179","volume":"138","author":"RN Alcalay","year":"2015","unstructured":"Alcalay, R. N. et al. Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations. Brain 138, 2648\u20132658 (2015).","journal-title":"Brain"},{"key":"1175_CR11","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1111\/febs.14393","volume":"285","author":"ME Gegg","year":"2018","unstructured":"Gegg, M. E. & Schapira, A. H. V. The role of glucocerebrosidase in Parkinson disease pathogenesis. FEBS J. 285, 3591\u20133603 (2018).","journal-title":"FEBS J."},{"key":"1175_CR12","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/brain\/aws095","volume":"135","author":"EB Vitner","year":"2012","unstructured":"Vitner, E. B., Farfel-Becker, T., Eilam, R., Biton, I. & Futerman, A. H. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher\u2019s disease. Brain 135, 1724\u20131735 (2012).","journal-title":"Brain"},{"key":"1175_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","volume":"6","author":"HJ Fernandes","year":"2016","unstructured":"Fernandes, H. J. et al. ER stress and autophagic perturbations lead to elevated extracellular alpha-synuclein in GBA-N370S Parkinson\u2019s iPSC-derived dopamine neurons. Stem Cell Rep. 6, 342\u2013356 (2016).","journal-title":"Stem Cell Rep."},{"key":"1175_CR14","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.wnl.0000276989.17578.02","volume":"69","author":"LN Clark","year":"2007","unstructured":"Clark, L. N. et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 69, 1270\u20131277 (2007).","journal-title":"Neurology"},{"key":"1175_CR15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mds.26071","volume":"30","author":"K Brockmann","year":"2015","unstructured":"Brockmann, K. et al. GBA-associated Parkinson\u2019s disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov. Disord. 30, 407\u2013411 (2015).","journal-title":"Mov. Disord."},{"key":"1175_CR16","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e318253d54b","volume":"78","author":"RN Alcalay","year":"2012","unstructured":"Alcalay, R. N. et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 78, 1434\u20131440 (2012).","journal-title":"Neurology"},{"key":"1175_CR17","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","volume":"36","author":"JR Mazzulli","year":"2016","unstructured":"Mazzulli, J. R. et al. Activation of beta-Glucocerebrosidase Reduces Pathological alpha-Synuclein and Restores Lysosomal Function in Parkinson\u2019s Patient Midbrain Neurons. J. Neurosci. 36, 7693\u20137706 (2016).","journal-title":"J. Neurosci."},{"key":"1175_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau6870","volume":"11","author":"LF Burbulla","year":"2019","unstructured":"Burbulla, L. F. et al. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson\u2019s disease. Sci. Transl. Med 11, eaau6870 (2019).","journal-title":"Sci. Transl. Med"},{"key":"1175_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.parkreldis.2021.02.003","volume":"84","author":"AE Kopytova","year":"2021","unstructured":"Kopytova, A. E. et al. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. Parkinsonism Relat. Disord. 84, 112\u2013121 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1175_CR20","doi-asserted-by":"publisher","first-page":"12101","DOI":"10.1073\/pnas.1108197108","volume":"108","author":"SP Sardi","year":"2011","unstructured":"Sardi, S. P. et al. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc. Natl Acad. Sci. USA 108, 12101\u201312106 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1175_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.14802\/jmd.23023","volume":"16","author":"YE Huh","year":"2023","unstructured":"Huh, Y. E., Usnich, T., Scherzer, C. R., Klein, C. & Chung, S. J. GBA1 variants and Parkinson\u2019s disease: paving the way for targeted therapy. J. Mov. Disord. 16, 261\u2013278 (2023).","journal-title":"J. Mov. Disord."},{"key":"1175_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nchembio850","volume":"3","author":"RL Lieberman","year":"2007","unstructured":"Lieberman, R. L. et al. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat. Chem. Biol. 3, 101\u2013107 (2007).","journal-title":"Nat. Chem. Biol."},{"key":"1175_CR23","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1073\/pnas.1300822110","volume":"110","author":"AH Schapira","year":"2013","unstructured":"Schapira, A. H. & Gegg, M. E. Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc. Natl Acad. Sci. USA 110, 3214\u20133215 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1175_CR24","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton, N. W. et al. Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N. Engl. J. Med 324, 1464\u20131470 (1991).","journal-title":"N. Engl. J. Med"},{"key":"1175_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37632-4","volume":"14","author":"A Gehrlein","year":"2023","unstructured":"Gehrlein, A. et al. Targeting neuronal lysosomal dysfunction caused by beta-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct. Nat. Commun. 14, 2057 (2023).","journal-title":"Nat. Commun."},{"key":"1175_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","volume":"50","author":"I Bendikov-Bar","year":"2013","unstructured":"Bendikov-Bar, I., Maor, G., Filocamo, M. & Horowitz, M. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol. Dis. 50, 141\u2013145 (2013).","journal-title":"Blood Cells Mol. Dis."},{"key":"1175_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin, S. et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 77, 427\u2013434 (2020).","journal-title":"JAMA Neurol."},{"key":"1175_CR28","doi-asserted-by":"publisher","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","volume":"284","author":"GH Maegawa","year":"2009","unstructured":"Maegawa, G. H. et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem. 284, 23502\u201323516 (2009).","journal-title":"J. Biol. Chem."},{"key":"1175_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/acn3.292","volume":"3","author":"A Narita","year":"2016","unstructured":"Narita, A. et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study. Ann. Clin. Transl. Neurol. 3, 200\u2013215 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1175_CR30","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1073\/pnas.1221046110","volume":"110","author":"C Yang","year":"2013","unstructured":"Yang, C. et al. Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc. Natl Acad. Sci. USA 110, 966\u2013971 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1175_CR31","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2017.08.004","volume":"25","author":"G Morabito","year":"2017","unstructured":"Morabito, G. et al. AAV-PHP.B-mediated global-scale expression in the mouse nervous system enables GBA1 gene therapy for wide protection from synucleinopathy. Mol. Ther. 25, 2727\u20132742 (2017).","journal-title":"Mol. Ther."},{"key":"1175_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","volume":"82","author":"EM Rocha","year":"2015","unstructured":"Rocha, E. M. et al. Glucocerebrosidase gene therapy prevents alpha-synucleinopathy of midbrain dopamine neurons. Neurobiol. Dis. 82, 495\u2013503 (2015).","journal-title":"Neurobiol. Dis."},{"key":"1175_CR33","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1073\/pnas.1220464110","volume":"110","author":"SP Sardi","year":"2013","unstructured":"Sardi, S. P. et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl Acad. Sci. USA 110, 3537\u20133542 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1175_CR34","doi-asserted-by":"publisher","first-page":"21200","DOI":"10.1073\/pnas.1119181109","volume":"108","author":"J Lu","year":"2011","unstructured":"Lu, J. et al. Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc. Natl Acad. Sci. USA 108, 21200\u201321205 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1175_CR35","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1073\/pnas.68.11.2810","volume":"68","author":"MW Ho","year":"1971","unstructured":"Ho, M. W. & O\u2019Brien, J. S. Gaucher\u2019s disease: deficiency of \u2018acid\u2019 -glucosidase and reconstitution of enzyme activity in vitro. Proc. Natl Acad. Sci. USA 68, 2810\u20132813 (1971).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1175_CR36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","volume":"37","author":"N Belmatoug","year":"2017","unstructured":"Belmatoug, N. et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur. J. Intern Med 37, 25\u201332 (2017).","journal-title":"Eur. J. Intern Med"},{"key":"1175_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrd.2017.214","volume":"17","author":"FM Platt","year":"2018","unstructured":"Platt, F. M. Emptying the stores: lysosomal diseases and therapeutic strategies. Nat. Rev. Drug Discov. 17, 133\u2013150 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1175_CR38","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1073\/pnas.1616152114","volume":"114","author":"SP Sardi","year":"2017","unstructured":"Sardi, S. P. et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc. Natl Acad. Sci. USA 114, 2699\u20132704 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1175_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00404-5","volume":"11","author":"C Viel","year":"2021","unstructured":"Viel, C. et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci. Rep. 11, 20945 (2021).","journal-title":"Sci. Rep."},{"key":"1175_CR40","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(23)00205-3","volume":"22","author":"N Giladi","year":"2023","unstructured":"Giladi, N. et al. Safety and efficacy of venglustat in GBA1-associated Parkinson\u2019s disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 22, 661\u2013671 (2023).","journal-title":"Lancet Neurol."},{"key":"1175_CR41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2406009121","volume":"121","author":"D Williams","year":"2024","unstructured":"Williams, D. et al. High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson\u2019s disease. Proc. Natl Acad. Sci. USA 121, e2406009121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1175_CR42","doi-asserted-by":"publisher","first-page":"167932","DOI":"10.1016\/j.jmb.2022.167932","volume":"435","author":"R Machtel","year":"2023","unstructured":"Machtel, R., Boros, F. A., Dobert, J. P., Arnold, P. & Zunke, F. From lysosomal storage disorders to parkinson\u2019s disease - challenges and opportunities. J. Mol. Biol. 435, 167932 (2023).","journal-title":"J. Mol. Biol."},{"key":"1175_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40035-024-00437-6","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang, X., Wu, H., Tang, B. & Guo, J. Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson\u2019s disease. Transl. Neurodegener. 13, 48 (2024).","journal-title":"Transl. Neurodegener."},{"key":"1175_CR44","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/1570159X11311020006","volume":"11","author":"LL Zou","year":"2013","unstructured":"Zou, L. L., Ma, J. L., Wang, T., Yang, T. B. & Liu, C. B. Cell-penetrating Peptide-mediated therapeutic molecule delivery into the central nervous system. Curr. Neuropharmacol. 11, 197\u2013208 (2013).","journal-title":"Curr. Neuropharmacol."},{"key":"1175_CR45","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/biomedicines11030728","volume":"11","author":"CN Keighron","year":"2023","unstructured":"Keighron, C. N. et al. Extracellular vesicles, cell-penetrating peptides and miRNAs as future novel therapeutic interventions for Parkinson\u2019s and Alzheimer\u2019s disease. Biomedicines 11, 728 (2023).","journal-title":"Biomedicines"},{"key":"1175_CR46","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1021\/acschembio.5b00753","volume":"11","author":"AS Dixon","year":"2016","unstructured":"Dixon, A. S. et al. NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem. Biol. 11, 400\u2013408 (2016).","journal-title":"ACS Chem. Biol."},{"key":"1175_CR47","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1021\/cb3002478","volume":"7","author":"MP Hall","year":"2012","unstructured":"Hall, M. P. et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem. Biol. 7, 1848\u20131857 (2012).","journal-title":"ACS Chem. Biol."},{"key":"1175_CR48","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1126\/science.1204592","volume":"332","author":"C Settembre","year":"2011","unstructured":"Settembre, C. et al. TFEB links autophagy to lysosomal biogenesis. Science 332, 1429\u20131433 (2011).","journal-title":"Science"},{"key":"1175_CR49","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.1174447","volume":"325","author":"M Sardiello","year":"2009","unstructured":"Sardiello, M. et al. A gene network regulating lysosomal biogenesis and function. Science 325, 473\u2013477 (2009).","journal-title":"Science"},{"key":"1175_CR50","volume":"12","author":"SD Kumar","year":"2025","unstructured":"Kumar, S. D. et al. Novel leech antimicrobial peptides, hirunipins: real-time 3D monitoring of antimicrobial and antibiofilm mechanisms using optical diffraction tomography. Adv. Sci. (Weinh.) 12, e2409803 (2025).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"1175_CR51","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.3233\/JPD-212739","volume":"11","author":"A Abeliovich","year":"2021","unstructured":"Abeliovich, A., Hefti, F. & Sevigny, J. Gene therapy for Parkinson\u2019s disease associated with GBA1 mutations. J. Parkinsons Dis. 11, S183\u2013S188 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"1175_CR52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1021\/cb900099e","volume":"4","author":"CJ Arthur","year":"2009","unstructured":"Arthur, C. J. et al. Structure and malonyl CoA-ACP transacylase binding of streptomyces coelicolor fatty acid synthase acyl carrier protein. ACS Chem. Biol. 4, 625\u2013636 (2009).","journal-title":"ACS Chem. Biol."},{"key":"1175_CR53","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/mds.25462","volume":"28","author":"B Dehay","year":"2013","unstructured":"Dehay, B. et al. Lysosomal impairment in Parkinson\u2019s disease. Mov. Disord. 28, 725\u2013732 (2013).","journal-title":"Mov. Disord."},{"key":"1175_CR54","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/mds.26562","volume":"31","author":"T Moors","year":"2016","unstructured":"Moors, T. et al. Lysosomal dysfunction and alpha-synuclein aggregation in Parkinson\u2019s disease: diagnostic links. Mov. Disord. 31, 791\u2013801 (2016).","journal-title":"Mov. Disord."},{"key":"1175_CR55","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1073\/pnas.87.4.1541","volume":"87","author":"M Pignatelli","year":"1990","unstructured":"Pignatelli, M., Durbin, H. & Bodmer, W. F. Carcinoembryonic antigen functions as an accessory adhesion molecule mediating colon epithelial cell-collagen interactions. Proc. Natl Acad. Sci. USA 87, 1541\u20131545 (1990).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1175_CR56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.nbd.2018.05.012","volume":"122","author":"CJ Cortes","year":"2019","unstructured":"Cortes, C. J. & La Spada, A. R. TFEB dysregulation as a driver of autophagy dysfunction in neurodegenerative disease: Molecular mechanisms, cellular processes, and emerging therapeutic opportunities. Neurobiol. Dis. 122, 83\u201393 (2019).","journal-title":"Neurobiol. Dis."},{"key":"1175_CR57","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1242\/jcs.146365","volume":"129","author":"G Napolitano","year":"2016","unstructured":"Napolitano, G. & Ballabio, A. TFEB at a glance. J. Cell Sci. 129, 2475\u20132481 (2016).","journal-title":"J. Cell Sci."},{"key":"1175_CR58","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ceb.2016.01.006","volume":"39","author":"LA Huber","year":"2016","unstructured":"Huber, L. A. & Teis, D. Lysosomal signaling in control of degradation pathways. Curr. Opin. Cell Biol. 39, 8\u201314 (2016).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1175_CR59","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1083\/jcb.101.6.2253","volume":"101","author":"HJ Geuze","year":"1985","unstructured":"Geuze, H. J., Slot, J. W., Strous, G. J., Hasilik, A. & von Figura, K. Possible pathways for lysosomal enzyme delivery. J. Cell Biol. 101, 2253\u20132262 (1985).","journal-title":"J. Cell Biol."},{"key":"1175_CR60","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.tins.2016.02.002","volume":"39","author":"H Martini-Stoica","year":"2016","unstructured":"Martini-Stoica, H., Xu, Y., Ballabio, A. & Zheng, H. The autophagy-lysosomal pathway in neurodegeneration: a TFEB perspective. Trends Neurosci. 39, 221\u2013234 (2016).","journal-title":"Trends Neurosci."},{"key":"1175_CR61","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"1175_CR62","doi-asserted-by":"publisher","first-page":"20051","DOI":"10.1073\/pnas.0908005106","volume":"106","author":"KC Luk","year":"2009","unstructured":"Luk, K. C. et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051\u201320056 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1175_CR63","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/nprot.2014.143","volume":"9","author":"LA Volpicelli-Daley","year":"2014","unstructured":"Volpicelli-Daley, L. A., Luk, K. C. & Lee, V. M. Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 9, 2135\u20132146 (2014).","journal-title":"Nat. Protoc."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01175-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01175-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01175-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:02:40Z","timestamp":1763560960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01175-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01175-w","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"323"}}